Table 1 Patient characteristics and clinical response
Patient number | Age/ sex | Leukemia type and genetic abnormalities | BM blasts burden | Prior lines of treatment | Prior immunotherapy | Dose of CAR-T cells: CD22 CAR#/CD19 CAR# | Clinical response |
|---|---|---|---|---|---|---|---|
1 | 26/M | Ph-like ALL (BCR-JAK2 fusion, IKZF1 deletion) | 64.93% | 4 | Blinatumomab | 1/1 | CR (MRD−) |
2 | 18/M | Ph−_ ALL (TP53 loss, NRAS mutation) | 0.33% (MRD+) | 4 | CD19 CAR-T | 1/1 | CR (MRD−) |
3 | 30/M | Ph−_ALL | 22.54% | 4 | Blinatumomab | 1/1 | CR (MRD−) |
4 | 40/M | Ph+-ALL (V299L mutaion) | 0.19% (MRD+) | 2 | No | 1/1 | CR (MRD−) |